Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Modalis Receives Japanese Patent for DUX4 Gene-Targeted Therapy for Facioscapulohumeral Muscular Dystrophy
Business Plans and Matters Related to High Growth Potential
Business and Financial report for Six Months Ended June 30, 2025
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Consolidated Financial Results for the Six Months Ended June 30, 2025 [Japanese GAAP]
Modalis Therapeutics, First Half Net Income Loss Widens, Apr-Jun Net Income Loss Widens
Modalis Therapeutics to Present Epigenome Editing Technology and Preclinical Data at the 6th Annual Genome Editing Therapeutics Summit
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
U.S. Patent Granted for Muscular Dystrophy Therapy Targeting LAMA1
Modalis Therapeutics to Present MDL-101, a Muscle-Tropic AAV Vectors for the Treatment of LAMA2-CMD using CRISPR-GNDM epigenome editing technology
MODALIS Therapeutics and The Broad Institute Enter into License Agreement to Advance Therapies for LAMA2-Related Muscular Dystrophy
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration
Notice of Outlook for IND Filing of MDL-101
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Modalis Therapeutics to participate in Nikkei Biotech Days conference
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration